Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19 (Q95801846)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16116487%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

title

Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16116487%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16116487%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

author name string

R Timm

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16116487%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

R Kaiser

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16116487%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

U Heider

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16116487%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

O Sezer

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16116487%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

K Weisz

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16116487%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

M Montemurro

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16116487%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

I Roots

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16116487%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

I Cascorbi

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16116487%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

publication date

1 January 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16116487%20AND%20SRC:MED&resulttype=core&format=json

The Pharmacogenomics Journal

30 May 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16116487%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16116487%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16116487%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

page(s)

365-373

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16116487%20AND%20SRC:MED&resulttype=core&format=json

Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma

30 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500330

7 January 2021

Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500330

7 January 2021

High-dose chemotherapy in breast cancer--interpretation of the randomized trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500330

7 January 2021

Dual purpose: some cancer therapies used to treat autoimmune diseases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500330

7 January 2021

Strategies for preservation of ovarian and testicular function after immunosuppression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500330

7 January 2021

A phase II study of carboplatin and cyclophosphamide in advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500330

7 January 2021

Cyclophosphamide toxicity. Characterising and avoiding the problem

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500330

7 January 2021

Complications of cyclophosphamide therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500330

7 January 2021

Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500330

7 January 2021

Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500330

7 January 2021

Baculovirus vectors: novel mammalian cell gene-delivery vehicles and their applications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500330

7 January 2021

The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500330

7 January 2021

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500330

7 January 2021

The genetic determinants of the CYP3A5 polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500330

7 January 2021

Characterization of the cytochrome P450 involved in side-chain oxidation of cyclophosphamide in humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500330

7 January 2021

Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500330

7 January 2021

Metabolism of oxazaphosphorines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500330

7 January 2021

Identification of human liver aldehyde dehydrogenases that catalyze the oxidation of aldophosphamide and retinaldehyde

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500330

7 January 2021

Metabolism of cyclophosphamide by aldehyde dehydrogenases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500330

7 January 2021

Induction of cytochrome P450 2B6 and 3A4 expression by phenobarbital and cyclophosphamide in cultured human liver slices.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500330

7 January 2021

A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500330

7 January 2021

Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500330

7 January 2021

Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500330

7 January 2021

Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500330

7 January 2021

Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500330

7 January 2021

CYP3A5 phenotype-genotype correlations in a British population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500330

7 January 2021

Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500330

7 January 2021

Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500330

7 January 2021

Identifiers

DOI

10.1038/SJ.TPJ.6500330

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16116487%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

1 reference